Literature DB >> 4208528

Isolation of substances responsible for lymphokine activity from sensitized mouse spleen cells.

P L Sandok, R D Hinsdill, R M Albrecht.   

Abstract

Cultures of brucella-sensitized mouse spleen cells exposed to Brucella abortus antigens in vitro release macrophage migration inhibition factor (MIF) and macrophage spreading factor. Subjecting the supernatants from such cultures to preparative scale electrophoresis in acrylamide gel yields several fractions, one of which contains both MIF and macrophage spreading factor. This material has properties attributable to guinea pig MIF: it is nondialyzable, heat stable, nontoxic to macrophages from heterologous murine donors, and has a greater anodal electrophoretic mobility than guinea pig serum albumin. Another fraction from the gel column inhibits macrophage spreading; its electrophoretic mobility is similar to that of guinea pig gamma globulin. Neither brucella antigen nor skin reactive substances were detectable in any acrylamide gel column fraction when tested by the mouse footpad induration assay technique.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4208528      PMCID: PMC414930          DOI: 10.1128/iai.9.6.1045-1050.1974

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Effect of lymphocyte mediators on macrophages in vitro. A correlation of morphological and cytochemical changes.

Authors:  I Nath; L W Poulter; J L Turk
Journal:  Clin Exp Immunol       Date:  1973-03       Impact factor: 4.330

Review 2.  The biological activities of soluble lymphocyte products.

Authors:  E Pick; J L Turk
Journal:  Clin Exp Immunol       Date:  1972-01       Impact factor: 4.330

3.  Role of lymphocyte activation products (LAP) in cell-mediated immunity. I. Preparation and partial purification of guinea-pig LAP.

Authors:  D C Dumonde; D A Page; M Matthew; R A Wolstencroft
Journal:  Clin Exp Immunol       Date:  1972-01       Impact factor: 4.330

4.  In vitro studies of delayed-type hypersensitivity. The time course of the primary immunological reaction in individual rats determined by macrophage spreading inhibition.

Authors:  B Veselic; D Dekaris; K M Hrsak
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

5.  In vitro studies on the mechanism of macrophage migration inhibition in tuberculin sensitivity.

Authors:  E R Heise; S Han; R S Weiser
Journal:  J Immunol       Date:  1968-11       Impact factor: 5.422

6.  Migration inhibition of mouse macrophages by Brucella antigens.

Authors:  P L Sandok; R D Hinsdill; R M Albrecht
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

7.  Production and characterization of migration inhibitory factor(s) (MIF) of established lymphoid and non-lymphoid cell lines.

Authors:  P S Papageorgiou; W L Henley; P R Glade
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

8.  Macrophage Migration Inhibition Studies with Cells from Mice Vaccinated with Cell Walls of Mycobacterium bovis BCG: Characterization of the Experimental System.

Authors:  K Yamamoto; R L Anacker
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

9.  THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCE.

Authors:  G B MACKANESS
Journal:  J Exp Med       Date:  1964-07-01       Impact factor: 14.307

10.  Glucocorticoid suppression of macrophage migration inhibitory factor.

Authors:  J E Balow; A S Rosenthal
Journal:  J Exp Med       Date:  1973-04-01       Impact factor: 14.307

View more
  2 in total

1.  Murine macrophage-lymphocyte interactions: scanning electron microscopic study.

Authors:  R M Albrecht; R D Hinsdill; P L Sandok; S D Horowitz
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

2.  Alterations in mouse macrophage migration: a function of assay systems, lymphocyte activation product preparation, and fractionation.

Authors:  P L Sandok; R D Hinsdill; R M Albrecht
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.